2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one Basic information
- Product Name:
- 2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
- Synonyms:
-
- 2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
- AGI-25696
- Pyrazolo[1,5-a]pyrimidin-7(4H)-one, 2,3-diphenyl-6-(6-quinolinyl)-
- Inhibitor,AGI-25696,AGI25696,AGI 25696,inhibit
- CAS:
- 2201066-35-3
- MF:
- C27H18N4O
- MW:
- 414.46
- Mol File:
- 2201066-35-3.mol
More
Less
2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one Chemical Properties
- Boiling point:
- 638.6±65.0 °C(Predicted)
- Density
- 1.30±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- pka
- 4.46±0.10(Predicted)
- InChI
- InChI=1S/C27H18N4O/c32-27-22(20-13-14-23-21(16-20)12-7-15-28-23)17-29-26-24(18-8-3-1-4-9-18)25(30-31(26)27)19-10-5-2-6-11-19/h1-17,29H
- InChIKey
- VJMSOWXHWUORTA-UHFFFAOYSA-N
- SMILES
- C12=C(C3=CC=CC=C3)C(C3=CC=CC=C3)=NN1C(=O)C(C1=CC=C3C(=C1)C=CC=N3)=CN2
More
Less
2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one Usage And Synthesis
Uses
AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
References
[1] Agios. Targeting MAT2A in MTAP-deleted Cancers. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, Chicago, IL, USA
2,3-diphenyl-6-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-oneSupplier
Taizhou Chuanxu Pharmaceutical Technology Co., Ltd. Gold
- Tel
- 13000000000
- 974144639@qq.com
Shanghai Rechem science Co., Ltd.
- Tel
- 021-31433387 15618786686
- sales@rechemscience.com
Shanghai Chaolan Chemical Technology Center
- Tel
- 021-QQ:65489617 15618227136
- Sales@ATKchemical.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Changzhou Chenhong Biotechnology Co., Ltd.
- Tel
- +86-0519-85788828 +86-13775037613
- sales@chemrenpharm.com